Article Figures & Data
Additional Files
Supplementary Data
- Supplementary Figures 1-7 - Supplementary Figure 1. Quantification of immunoblotting in Figure 1. Supplementary Figure 2. Animal weights from Figure 3 xenografts. Supplementary Figure 3. Quantification of immunoblotting from xenograft tissues in Figure 3. Supplementary Figure 4. Viability of GSI combination therapy with anti-androgens Enzalutamide or Abiraterone. Supplementary Figure 5. GSI and anti-Androgen therapies synergize to decrease colony formation of CRPC cells. Supplementary Figure 6. GSIs synergize with anti-androgens Enzalutamide and Abiraterone to inhibit prostate cancer cell migration in vitro. Supplementary Figure 7. Matrigel Dot assay performed on 22RV1 cells was not able to assay migration.